Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCLA-129 Combined with Befotertinib in EGFR-Mutated NSCLC
NCT06015568Phase 1Not yet recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Nov 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pamvatamig in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerable Dose at 28 days and 2 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
pamvatamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06015568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06015568.